Immuneering (NASDAQ: IMRX) grants CSO 344,000 stock options

Rhea-AI Filing Summary

Immuneering Corp's chief scientific officer, Brett Matthew Hall, reported a new stock option grant. On February 3, 2026, he was awarded options to purchase 344,000 shares of Class A common stock at an exercise price of $4.91 per share.

The options vest in equal monthly installments over four years, starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. After this grant, Hall beneficially owns 344,000 stock options, all held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Brett Matthew

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.91	02/03/2026		A		344,000		(1)	02/03/2036	Class A Common Stock	344,000	$0	344,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Brett Matthew Hall	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Immuneering (IMRX) disclose in this Form 4 filing?

Immuneering disclosed that chief scientific officer Brett Matthew Hall received a grant of 344,000 stock options on February 3, 2026. These options relate to the company’s Class A common stock and are recorded as a derivative security held directly by the executive.

How many stock options did Immuneering’s CSO receive and at what price?

Brett Matthew Hall was granted 344,000 stock options for Immuneering Class A common stock with an exercise price of $4.91 per share. This price is what he must pay per share if he chooses to exercise the options in the future.

What is the vesting schedule for Brett Matthew Hall’s Immuneering options?

The options vest in equal monthly installments over four years, beginning on February 1, 2026. According to the filing, they are expected to be fully vested and exercisable on January 1, 2030, assuming continued service through the vesting period.

How many Immuneering stock options does the CSO own after this transaction?

After this grant, Brett Matthew Hall beneficially owns 344,000 stock options in Immuneering Corp. The filing indicates these derivative securities are held directly, reflecting his total reported option holdings following the February 3, 2026 transaction.

What role does Brett Matthew Hall hold at Immuneering (IMRX)?

Brett Matthew Hall serves as chief scientific officer of Immuneering Corp, as indicated in the Form 4. His position is important because the filing reports insider equity compensation awarded to a senior officer responsible for the company’s scientific and research activities.